Leerink Partnrs Issues Positive Forecast for TNDM Earnings

Key Points

• Leerink Partners has raised its FY2028 earnings per share estimate for Tandem Diabetes Care from $0.42 to $0.53, despite the current consensus estimate indicating a loss of ($1.68) per share for the year.
• Tandem Diabetes Care's stock performance remains mixed, trading at $11.22 with a 1-year range between $9.98 and $47.60, while facing multiple downward adjustments in price targets from several analysts.
• The company reported a quarterly revenue of $240.68 million, which was above analyst expectations, though it posted a loss of ($0.48) EPS, missing the consensus estimate.

Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) - Equities research analysts at Leerink Partnrs lifted their FY2028 EPS estimates for shares of Tandem Diabetes Care in a research note issued on Wednesday, August 6th. Leerink Partnrs analyst M. Kratky now anticipates that the medical device company will earn $0.53 per share for the year, up from their previous forecast of $0.42. The consensus estimate for Tandem Diabetes Care's current full-year earnings is ($1.68) per share.

TNDM has been the subject of several other research reports. Barclays reduced their target price on shares of Tandem Diabetes Care from $53.00 to $51.00 and set an "overweight" rating for the company in a research note on Friday. Stifel Nicolaus decreased their price target on shares of Tandem Diabetes Care from $60.00 to $31.00 and set a "buy" rating on the stock in a research note on Thursday, May 1st. UBS Group decreased their target price on shares of Tandem Diabetes Care from $20.00 to $17.00 and set a "neutral" rating on the stock in a research report on Thursday. Wall Street Zen cut shares of Tandem Diabetes Care from a "hold" rating to a "sell" rating in a research report on Saturday, June 21st. Finally, Mizuho assumed coverage on shares of Tandem Diabetes Care in a research report on Thursday, April 10th. They set a "neutral" rating and a $20.00 price target on the stock. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $25.67.

Tandem Diabetes Care Stock Performance

NASDAQ:TNDM traded down $0.30 during trading hours on Friday, reaching $11.22. 1,495,177 shares of the company's stock were exchanged, compared to its average volume of 1,660,444. Tandem Diabetes Care has a 1-year low of $9.98 and a 1-year high of $47.60. The firm has a market capitalization of $747.33 million, a price-to-earnings ratio of -3.63 and a beta of 1.46. The company has a quick ratio of 1.81, a current ratio of 2.30 and a debt-to-equity ratio of 1.99. The company has a 50-day moving average of $17.73 and a 200 day moving average of $21.72.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last issued its earnings results on Wednesday, August 6th. The medical device company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by ($0.08). The company had revenue of $240.68 million during the quarter, compared to analyst estimates of $238.39 million. Tandem Diabetes Care had a negative net margin of 20.51% and a negative return on equity of 59.02%. The company's quarterly revenue was up 8.5% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.47) EPS.

Institutional Trading of Tandem Diabetes Care

Institutional investors and hedge funds have recently bought and sold shares of the stock. Assetmark Inc. raised its holdings in Tandem Diabetes Care by 42.9% during the 1st quarter. Assetmark Inc. now owns 1,750 shares of the medical device company's stock worth $34,000 after buying an additional 525 shares during the period. NBC Securities Inc. bought a new stake in shares of Tandem Diabetes Care in the 1st quarter valued at approximately $37,000. CWM LLC grew its stake in shares of Tandem Diabetes Care by 262.6% in the 2nd quarter. CWM LLC now owns 2,796 shares of the medical device company's stock valued at $52,000 after buying an additional 2,025 shares in the last quarter. Brooklyn Investment Group grew its stake in shares of Tandem Diabetes Care by 417.8% in the 1st quarter. Brooklyn Investment Group now owns 3,397 shares of the medical device company's stock valued at $65,000 after buying an additional 2,741 shares in the last quarter. Finally, Nisa Investment Advisors LLC grew its stake in shares of Tandem Diabetes Care by 186.9% in the 2nd quarter. Nisa Investment Advisors LLC now owns 4,171 shares of the medical device company's stock valued at $78,000 after buying an additional 2,717 shares in the last quarter.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.